Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma

Leukemia

Volumn 29, Issue 7, 2015, Pages 1564-1570

  Horn, H ^a   Ziepert, M ^b   Wartenberg, M ^c   Staiger, A M ^a   Barth, T F E ^d   Bernd, H W ^e   Feller, A C ^e   Klapper, W ^f   Stuhlmann Laeisz, C ^f   Hummel, M ^g   Stein, H ^h   Lenze, D ^g   Hartmann, S ⁱ   Hansmann, M L ⁱ   Moller P ^d   Cogliatti, S ^j   Pfreundschuh, M ^k   Trumper L ^l   Loeffler, M ^b   Glass, B ^m   Schmitz, N ^m   Ott, G ⁿ   Rosenwald, A ^c   more..

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d UNIVERSITY HOSPITAL ULM   (Germany)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^f UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h Pathodiagnostik Berlin   (Germany)

ⁱ UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^j CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^k SAARLAND UNIVERSITY   (Germany)

^l UNIVERSITY OF GÖTTINGEN   (Germany)

^m DEPARTMENT OF CARDIOLOGY   (Germany)

ⁿ ROBERT BOSCH HOSPITAL   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD5 ANTIGEN; INTERFERON REGULATORY FACTOR 4; PARAFFIN; PROTEIN BCL 2; RITUXIMAB; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXP1; UNCLASSIFIED DRUG; MYC PROTEIN; TUMOR MARKER;

ADULT; ARTICLE; CANCER PROGNOSIS; CLINICAL TRIAL; FEMALE; GENE REARRANGEMENT; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IN SITU HYBRIDIZATION; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MARKER GENE; MIDDLE AGED; OVERALL SURVIVAL; PRIORITY JOURNAL; RISK FACTOR; SURVIVAL TIME; ADOLESCENT; CANCER STAGING; COMPARATIVE STUDY; ENZYME IMMUNOASSAY; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENETICS; METABOLISM; MORTALITY; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; SURVIVAL RATE; YOUNG ADULT;

ADOLESCENT; ADULT; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MYC; RISK FACTORS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84937022940     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.43     Document Type: Article

References (36)

1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. (eds). WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. International Agency for Research on Cancer: Lyon, France, 2008
2. Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, Pfreundschuh M, et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol. 2010; 28: 2373-2380
3. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. New Engl J Med. 2002; 346: 1937-1947
4. Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, et al. Stromal Gene Signatures in large-B-cell Lymphomas. New Engl J Med. 2008; 359: 2313-2323
5. Karlin L, Coiffier B. Improving survival and preventing recurrence of diffuse large B-cell lymphoma in younger patients: current strategies and future directions. Onco Targets Ther. 2013; 6: 289-296
6. Ott G, Ziepert M, Klapper W, Horn H, Szczepanowski M, Bernd HW, et al. Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. Blood. 2010; 116: 4916-4925
7. Coutinho R, Clear AJ, Owen A, Wilson A, Matthews J, Lee A, et al. Poor concordance among nine immunohistochemistry classifiers of cell-of-origin for diffuse large B-cell lymphoma: implications for therapeutic strategies. Clin Cancer Res. 2013; 19: 6686-6695
8. Salles G, de Jong D, Xie W, Rosenwald A, Chhanabhai M, Gaulard P, et al. Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. Blood. 2011; 117: 7070-7078
9. Horn H, Ziepert M, Becher C, Barth TFE, Bernd HW, Feller AC, et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood. 2013; 121: 2253-2263
10. Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, Rogic S, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012; 30: 3452-3459
11. Green TM, Young KH, Visco C, Xu-Monette ZY, Orazi A, Go RS, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012; 30: 3460-3467
12. Tzankov A, Xu-Monette ZY, Gerhard M, Visco C, Dirnhofer S, Gisin N, et al. Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Mod Pathol. 2014; 27: 958-971
13. Hu S, Xu-Monette ZY, Tzankov A, Green T, Wu L, Balasubramanyam A, et al. MYC/BCL2 protein co-expression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2013; 121: 4021-4031
14. Valera A, López-Guillermo A, Cardesa-Salzmann T, Climent F, González-Barca E, Mercadal S, et al. MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Haematologica. 2013; 98: 1554-1562
15. Schmitz N, Nickelsen M, Ziepert M, Haenel M, Borchmann P, Schmidt C, et al. Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (R-MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). Lancet Oncol. 2012; 13: 1250-1259
16. Lennert K, Feller A. Histopathology of Non-Hodgkińs Lymphomas. Springer Verlag: New York, USA, 1992
17. Horn H, Bausinger J, Staiger AM, Sohn M, Schmelter C, Kim G, et al. Numerical and structural genomic aberrations are reliably detectable in tissue microarrays of formalin-fixed paraffin-embedded tumor samples by fluorescence in situ hybridization. PLoS One. 2014; 9: e95047
18. Meyer PN, Fu K, Greiner TC, Smith LM, Delabie J, Gascoyne RD, et al. Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. J Clin Oncol. 2011; 29: 200-207
19. Fleiss JL. Measuring nominal scale agreement among many raters. Psychol Bull. 1971; 76: 378-382
20. Hans CP, Weisenburger DD, Greiner TC, Chan WC, Aoun P, Cochran GT, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004; 103: 275-282
21. Muris JJ, Ylstra B, Cillessen SA, Ossenkoppele GJ, Kluin-Nelemans JC, Eijk PP, et al. Profiling of apoptosis genes allows for clinical stratification of primary nodal diffuse large B-cell lymphomas. Br J Haematol. 2007; 36: 38-47
22. Nyman H, Jerkeman M, Karjalainen-Lindsberg ML, Banham AH, Leppä S. Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP. Mod Pathol. 2009; 22: 1094-1101
23. Choi WW, Weisenburger DD, Greiner TC, Piris MA, Banham AH, Delabie J, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res. 2009; 15: 5494-5502
24. Barrans SL, Crouch S, Smith A, Worrillow L, Smith A, Patmore R, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol. 2010; 28: 3360-3365
25. Savage KJ, Johnson NA, Ben-Neriah S, Connors JM, Sehn LH, Farinha P, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients Ttreated with R-CHOP chemotherapy. Blood. 2009; 114: 3533-3537
26. Akyurek N, Uner A, Benekli M, Barista I. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab. Cancer. 2011; 118: 4173-4183
27. Copie-Bergman C, Gaulard P, Leroy K, Briere J, Baia M, Jais JP, et al. Immunofluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study. J Clin Oncol. 2009; 27: 5573-5579
28. Iqbal J, Meyer PN, Smith LM, Johnson NA, Vose JM, Greiner TC, et al. BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab. Clin Cancer Res. 2011; 17: 7785-7795
29. Visco C, Tzankov A, Xu-Monette ZY, Miranda RN, Tai YC, Li Y, et al. Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study. Haematologica. 2013; 98: 255-263
30. de Jong D, Koster A, Hagenbeek A, Raemaekers J, Veldhuizen D, Heisterkamp S, et al. Impact of tumor microenvironment on prognosis in follicular lymphoma is dependent of specific treatment protocols. Haematologica. 2009; 94: 70-77
31. Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006; 7: 379-391
32. Klapper W, Kreuz M, Kohler CW, Burkhardt B, Szczepanowski M, Salaverria I, et al. Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma. Blood. 2012; 119: 1882-1887
33. Szczepanski T, Harrison CJ, van Dongen JJ. Genetic aberrations in paediatric acute leukaemias and implications for management of patients. Lancet Oncol. 2010; 11: 880-889
34. Oschlies I, Salaverria I, Mahn F, Meinhardt A, Zimmermann M, Woessmann W, et al. Pediatric follicular lymphoma-A clinico-pathological study of a population-based series of patients treated within the Non-Hodgkin's Lymphoma-Berlin-Frankfurt-Munster (NHL-BFM) multicenter trials. Haematologica. 2010; 95: 253-259
35. Masqué-Soler N, Szczepanowski M, Kohler CW, Spang R, Klapper W. Molecular classification of mature aggressive B-cell lymphoma using digital multiplexed gene expression on formalin-fixed paraffin-embedded biopsy specimens. Blood. 2013; 122: 1985-1986
36. Scott DW, Wright GW, Williams PM, Lih CJ, Walsh W, Jaffe ES, et al. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood. 2014; 123: 1214-1217